Lara Gut-Behrami Joins Avea Life as Investor, Chief Female Performance Officer and Advisory Board Member

Lara Gut-Behrami has invested in Avea Life and joined the Swiss longevity company as Chief Female Performance Officer, brand ambassador and Advisory Board member, startupticker.ch reported on October 20, 2026. The four-year partnership follows Avea Life's CHF 21 million in 2025 revenue, a 50% increase over the previous year.

Gut-Behrami's Roles at Avea Life

Gut-Behrami is taking a stake in the Zug-based company as part of a four-year partnership that the company describes as going beyond a traditional brand endorsement. She will contribute to Avea Life's strategic development as a shareholder and Advisory Board member, drawing on 18 years of experience in elite sport. The collaboration will focus on female health, performance and recovery, with the aim of supporting women at different stages of life in strengthening their performance, energy and recovery over the long term.

Sophie Chabloz, CSO of Avea Life, said: "With Lara, we are gaining someone who understands stress, recovery and sustainable performance from personal experience. Her perspective will enrich our work in female health in a valuable way."

Avea Life develops science-oriented products for healthy ageing, cellular energy, skin health, sleep, metabolism and gut health. Its portfolio comprises 11 dietary supplements and one serum, including NMN for NAD+ support, an antioxidant formula called Booster, and a vegan Collagen Activator. The company most recently launched MenoSpan, a hormone-free formula designed to support mood, mental clarity and reduced tiredness. Products are sold through Avea Life's website, Amazon and approximately 50 retail locations across Switzerland, Germany and Italy. As of July 2026, Avea Life had served more than 250,000 customers and had over 15,000 active subscribers. The company employs 40 people and has raised approximately CHF 7 million in investment capital to date.

Avea Life's Funding and Product Record

According to akta.pro company records, Avea Life has three funding rounds on record: a $2.6 million seed in June 2022 led by Maximon, a $2.8 million seed in February 2023, and a $2.2 million seed in November 2023. The same records list a February 2025 patent for Colgevity, a vegan collagen precursor co-developed with ETH Zurich and validated in Nature's npj Aging, and a January 2025 launch of an at-home NAD+ Test alongside the B2B-exclusive NR Vitaliser. Avea Life reached 100,000 customer orders via the Shopify platform by June 2025 and expanded its range to 12 supplements.

Leadership Moves Across Healthcare

THL Partners appointed Bruce Robertson as Managing Director on its healthcare investment team on October 19, 2026, joining from H.I.G. Capital, citybiz reported. Shenandoah Therapeutics named Steve Worland CEO and Isabella Graef Chief Scientific Officer on October 14, 2026, with the company having raised $21.5 million in seed financing in 2025, according to citybiz. Main Sequence promoted Dr. Elaine Stead from Principal to Partner on October 13, 2026, ahead of its fourth fund, Startup Researcher reported.

Davion Healthcare's Nasdaq Date

Davion Healthcare expects its ordinary shares to begin trading on Nasdaq on October 22, 2026, under ticker DAVI, Stock Titan reported. The company appointed Glenn Williams as CEO and Jeremy North as COO, launched a £30 million bond to fund acquisitions, and established an Operational Directorate to lead commercialisation and growth.